ImmunoForge Heads to JPM 2026 to Seek Global Partners for FDA-Cleared Phase 2 Assets
Clinical-stage biotech ImmunoForge Co., Ltd. is taking a focused partnering approach at the 43rd Annual J.P. Morgan Healthcare Conference (JPM 2026) in San Francisco.
Instead of a public stage presentation, the company will hold private 1-on-1 meetings with global pharma companies and investors from January 12–15, 2026.
The goal is clear: secure strategic partners to lead U.S. clinical development for its FDA-cleared Phase 2 programs.
Why JPM 2026 Matters for ImmunoForge?
ImmunoForge enters JPM week with something many early biotechs lack, de-risked assets.
Several pipeline candidates already hold U.S. FDA Phase 2 IND clearances, allowing partners to move straight into trials without regulatory delay.
As a lean organization, ImmunoForge is now prioritizing licensing deals, co-development partnerships, and NewCo models.
Core Technologies Driving the Pipeline
At the center of ImmunoForge’s strategy is its proprietary ELP (Elastin-Like Polypeptide) platform.
Key platform advantages include:
- Monthly long-acting ELP platform, enabling peptide conjugation and protein fusion
- BBB-penetrating ELP platform, designed to shuttle drugs across the blood–brain barrier for CNS indications
These platforms aim to reduce dosing frequency while improving patient compliance.
Lead Assets Open for U.S. Partnerships
ImmunoForge is actively discussing partnerships for multiple clinical-stage programs:
PF1801 – Muscle & Metabolic Disorders
- Indications: Polymyositis, Dermatomyositis, DMD, Sarcopenia
- Status: Phase 2 in South Korea
- U.S. FDA Phase 2 IND clearance already granted
PF1804 – DMD-Associated Cardiomyopathy
- Status: FDA Phase 2 IND cleared
- Ready for immediate U.S. clinical execution
PF1807 – Sarcopenia
- Monthly therapy targeting muscle degeneration
- Protected by use patents for myositis and sarcopenia
KF1601 – Chronic Myeloid Leukemia (CML)
- Korea rights licensed ahead of Phase 1
- Global rights (ex-Korea) available for licensing
A Partner-First Strategy
ImmunoForge is positioning itself as a science-ready, execution-light biotech. According to the company, FDA clearances were pursued early to remove friction for future partners.
Beyond traditional licensing, the company is also open to investor-led NewCo structures to accelerate global development.
Meeting Requests During JPM 2026
ImmunoForge is currently accepting meeting requests for JPM week.
About ImmunoForge
ImmunoForge is a venture-backed, clinical-stage biopharmaceutical company focused on rare and muscular diseases. Its proprietary ELP platform enables weekly or monthly dosing for peptide-based drugs.
The company’s mission is simple: de-risk early, partner smart, and move fast toward patients.
